Cart
sales@molnova.com
Rezvilutamide
CAS No. 1572045-62-5
Rezvilutamide( —— )
Catalog No. M35089 CAS No. 1572045-62-5
Rezvilutamide (SHR3680) is an orally available androgen receptor inhibitor that crosses the blood-brain barrier and has antitumor activity.Rezvilutamide (SHR3680) is used in the study of metastatic desmoplasia-resistant prostate cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 112 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRezvilutamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionRezvilutamide (SHR3680) is an orally available androgen receptor inhibitor that crosses the blood-brain barrier and has antitumor activity.Rezvilutamide (SHR3680) is used in the study of metastatic desmoplasia-resistant prostate cancer.
-
DescriptionRezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1572045-62-5
-
Formula Weight479.47
-
Molecular FormulaC22H20F3N3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (208.56 mM; Ultrasonic )
-
SMILESCC1(C)N(C(=S)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F)c1ccc(OC[C@@H](O)CO)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. SangjunYoo, et al. New drugs in prostate cancer. Prostate International Volume 4, Issue 2, June 2016, Pages 37-42.
molnova catalog
related products
-
3-(7,7-dimethyl-5-ox...
3-[7 ,7- dimethyl-5-oxo -6H-pyrrolo[3,4-b]pyridin-2-yI]-1H-indole-7 -carbonitrile is an androgen receptor modulator.
-
Dehydroepiandrostero...
DHEA (Dehydroisoandrosterone) is an important endogenous steroid hormone.
-
Ralaniten triacetate
Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
